IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v5y2021i1d10.1007_s41669-020-00220-z.html
   My bibliography  Save this article

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014

Author

Listed:
  • Christine M. Cramer-van der Welle

    (Santeon Hospital Group)

  • Bas J. M. Peters

    (St. Antonius Hospital)

  • Maarten J. Deenen

    (Catharina Hospital)

  • Franz M. N. H. Schramel

    (St Antonius Hospital)

  • Ewoudt M. W. Garde

    (St. Antonius Hospital
    Utrecht University)

Abstract

Background The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). Methods All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Results Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years (p = 0.437 and p = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010. Conclusion This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years.

Suggested Citation

  • Christine M. Cramer-van der Welle & Bas J. M. Peters & Maarten J. Deenen & Franz M. N. H. Schramel & Ewoudt M. W. Garde, 2021. "Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014," PharmacoEconomics - Open, Springer, vol. 5(1), pages 121-127, March.
  • Handle: RePEc:spr:pharmo:v:5:y:2021:i:1:d:10.1007_s41669-020-00220-z
    DOI: 10.1007/s41669-020-00220-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-020-00220-z
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-020-00220-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Tim A Kanters & Clazien A M Bouwmans & Naomi van der Linden & Siok Swan Tan & Leona Hakkaart-van Roijen, 2017. "Update of the Dutch manual for costing studies in health care," PLOS ONE, Public Library of Science, vol. 12(11), pages 1-11, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Journal round-up: PharmacoEconomics – Open 5(1)
      by Rita Faria in The Academic Health Economists' Blog on 2021-04-29 06:00:05

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Simone A. Huygens & Isaac Corro Ramos & Carlijn V. C. Bouten & Jolanda Kluin & Shih Ting Chiu & Gary L. Grunkemeier & Johanna J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken, 2020. "Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 557-572, June.
    2. Maria Gheorghe & Renske J. Hoefman & Matthijs M. Versteegh & Job Exel, 2019. "Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool," PharmacoEconomics, Springer, vol. 37(1), pages 93-103, January.
    3. Christine M. Cramer-van der Welle & Bas J. M. Peters & Maarten J. Deenen & Franz M. N. H. Schramel & Ewoudt M. W. Garde, 0. "Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014," PharmacoEconomics - Open, Springer, vol. 0, pages 1-7.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:5:y:2021:i:1:d:10.1007_s41669-020-00220-z. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: . General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.